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Abstract 
Aims: Review the current applications of Big Data in diabetes care and consider the future 
potential. 
Methods: Scoping study of the academic literature on Big Data and diabetes care. 
Results: Healthcare data are being produced at ever-increasing rates, and this information has 
the potential to transform the provision of diabetes care.  Big Data is beginning to have an 
impact on diabetes care through data research. The use of Big Data for routine clinical care is 
still a future application. 
  
Conclusions: Vast amounts of healthcare data are already being produced, and the key is 
harnessing these to produce actionable insights. Considerable development work is required to 
achieve these goals. 
 
Introduction 
Big Data and diabetes: background 
Diabetes mellitus is a common cause of morbidity and mortality across the globe. Type 2 
diabetes continues to rise in prevalence annually; from 1980 to 2004, Type 2 quadrupled in 
both prevalence and incidence (1).  This will be exacerbated further by the increase in 
obesity. It is estimated that diabetes will be the seventh leading cause of death worldwide 
by 2030 (2). 
Type 2 diabetes has a genetic influence, but is also strongly linked with food consumption 
and a sedentary lifestyle. The influence of diet is fundamental both in the development of 
diabetes and as the bedrock of treatment; recent studies have shown that  adherence to a 
very low calorie diet can avoid the need for anti-diabetes medication (3). Despite this, many 
people with diabetes do not have good control of their condition (4). Delays in diagnosis 
also prevent the commencement of suitable treatment. The costs of managing diabetic 
complications currently outweigh the costs of anti-diabetes drugs by a factor of 3-4 (5). 
These observations suggest that improved self-management could be a powerful tool in 
reduction of morbidity and mortality from type 2 diabetes, whether from prevention or 
improved glycaemic control. Research that can inform policy and guide management has 
the potential for large cost savings and to make a substantial impact on public health. 
As individuals we gather an increasing amount of data about ourselves. Activity trackers are 
one example of a wearable device that collects and collates health data. The Quantified Self 
movement emerged from the involvement of the patient in the collection of data in 
diabetes and other chronic diseases (6). The routine collection of large amounts of data is 
the essential bedrock of Big Data. The ubiquity of smartphones that have considerable 
computing power provides the opportunity to easily and cheaply exploit digital health 
technology (7). However, this use of personal digital assets also has the potential to increase 
disparities in diabetes health outcomes by means of the “digital divide” (8–10). 
The aim of this paper is to review the role and the potential of Big Data in diabetes care. 
Digital technology can assist in achieving the twin goals of improving care and lowering 
costs, and many of these innovations rely on Big Data. 
 
Big Data defined 
Requirements of Big Data 
  
Big Data is a term that is much used, in the literature on healthcare and other areas of 
research. Whilst there is no universally accepted definition, the term generally refers to a 
large dataset characterised by the ‘5 Vs’ [11]:  
1. Volume 
2. Variety 
3. Velocity 
4. Veracity 
5. Value 
‘Volume’ refers to the amount of data. Large datasets by themselves do not pose any 
unique challenges in analysis. ‘Variety’ refers to the different forms of data that are 
combined. There may be numerical, ordinal and nominal data. There may be semantic 
differences. For example, there are many different categories of cardiovascular disease. Not 
all of these are captured by all datasets. ‘Velocity’ refers to the speed at which processing is 
required to generate usable insights. ‘Veracity’ refers to the accuracy and reliability of the 
data; large amounts of poor-quality data provide no advantage over small amounts of poor- 
quality data. ‘Value’ refers to the intrinsic worth of the data i.e. does the data provide useful 
insights? Data that provides little value by itself may however provide great value when 
combined with other data.  
Not all five characteristics are required to constitute Big Data. Big Data is best defined by the 
requirement for special techniques and technologies to analyse a complex data set [12]. 
While Big Data research has great potential, it brings certain challenges (Table 1). 
Challenge Volume  Variety Velocity Veracity Value 
Managing large amounts of 
unstructured data 
Sheer 
volume of 
data 
Many 
different 
formats of 
data  
High 
performance 
computing 
required 
Data may be 
poor quality 
Some of the 
data may 
be 
worthless 
Integrating different 
datasets 
 Semantic 
differences 
Requires 
time to 
integrate 
Datasets 
may not all 
be equally 
reliable 
Datasets 
may not be 
equally 
valuable 
Consent Makes opt-in 
informed 
consent 
impracticable 
    
 
 
Data Acquisition 
The era of Big Data has been enabled by the routine collection of large amounts of data, 
increasingly cheap storage, and high-powered computing [13–15]. This enables the 
collection and processing of data about everything from what groceries are bought to where 
leisure activities take place and for how long. Healthcare has always produced large 
amounts of data, but historically not in a format conducive to easy analysis. The effects of 
  
Big Data on research are likely to be protean. For certain applications of Big Data, it may be 
sufficient to demonstrate correlations between variables  [16]. For example it  does not 
matter exactly why buying certain books or liking certain Facebook posts correlates with 
voting preference; it is the insight that matters [17]. However, this will usually not suffice for 
health-related Big Data; experience with data mining shows that spurious correlations occur 
at a high rate. For example, an association was found between ACE-inhibitors and 
hypoglycaemia. The apparent association disappeared once correction for a diagnosis of 
diabetes was made [18]. Predicating diagnostic or treatment strategies on these findings 
alone would therefore be perilous. This problem has been recognized since the advent of 
techniques trying to find hitherto unknown associations, such as post-marketing 
surveillance of drug safety (pharmacovigilance).  
Where routinely collected data are used for research, the scope of the research will be 
limited by the available data. For example, testing for glutamic acid decarboxylase 
antibodies (GADA) and C-peptide to classify the type of diabetes was not historically 
routinely performed in clinical practice on the grounds of expense. Genome analysis is not 
usually performed in publicly funded health systems. 
Although Big Data research often relies on amassing large amounts of heterogeneous data 
already collected for another purpose, large datasets are capable of supporting a number of 
different analyses depending on the selection of data from the overall set. All patients 
prescribed a particular drug can be extracted, or all patients of a certain age or from a 
certain area can be studied.  
Specialist datasets focussing on one condition (or at least one clinical specialty) will 
generally be superior in terms of data quality and interoperability. However, these datasets 
by definition will not contain all the healthcare episodes of a patient, and often not even all 
the episodes relevant to a particular condition. Our own experience in the Biolytica project 
to develop an analytics platform in which we used data from the Hicom Diamond diabetes 
database for a single diabetes service. Often important clinical data e.g. in relation to 
vascular disease and amputation was  entered as free text rather than as coded data (18). 
The entry of these details is not as reliable, and this makes accurate determination of 
complication rates difficult even if the required programming to harvest this from free text 
is devised. Sequelae of inpatient procedures that tend to present to primary care 
practitioners are likewise difficult to track. Linking different datasets is therefore the key to 
the big picture, if there are no all-inclusive electronic health records available. 
Although there are disadvantages to using routinely collected data for research, there are 
also advantages beyond the ease and cost of collection. There is a move towards the greater 
use of real world data, particularly in assessment of drug efficacy and adverse effects, 
because it represents actual practice (where a more heterogeneous population is treated, 
with polypharmacy, co-morbidities and extremes of age commonplace) (19). The ‘V’ of 
‘Velocity’ in Big Data makes it possible to find out what is happening to patients as it 
happens, which has many applications in detecting adverse effects or epidemics, for 
example.  
  
There has been much commentary about the potential for Big Data to transform healthcare, 
particularly by reducing or containing costs (20). There is no doubt that there are vast 
amounts of healthcare data; the challenge is exploiting them effectively There are 
significant barriers to achieving this potential, most notably the difficulty in combining 
datasets not least because of concerns over privacy with such sensitive data (21–23). 
It is also important to recognize the limitations of Big Data. Vast amounts of data cannot 
transform diabetes care unless the framework and support are available to translate them 
into meaningful action. If these are not in place, the use of “quick-fix” solutions could 
worsen inequalities due to the digital divide. For example, glucose monitoring alone does   
not improve outcomes, and indeed can have negative effects (24). 
Techniques of Big Data 
Big Data technologies open new opportunities for breakthroughs in healthcare data analysis 
by addressing different perspectives:  
• Descriptive: what happened 
• Diagnostic: why it happened 
• Predictive: what will happen  
• Prescriptive: how we can make it happen (25) 
There are a number of sources of Big Data, and a number of ways that Big Data can be used. 
Figure 1 illustrates some of the inputs and outputs of medical Big Data. 
 
In particular, there are data mining (aka knowledge discovery) and machine learning 
techniques. These can be supervised (where the algorithm learns on a labelled dataset, 
providing an answer key that the algorithm can use to evaluate its accuracy on training data) 
or unsupervised (where the algorithm tries to make sense of unlabelled data by extracting 
features and patterns on its own).  
  
Data mining is the process of extracting knowledge from a data set. This entails a number of 
steps. Most importantly, the dataset must be confirmed as suitable for the proposed study – 
are the proposed data present in sufficient quantity and quality? There is often a need for 
cleaning and pre-processing, and these steps may reveal data quality issues that affect the 
research eg faulty data entry giving numbers outside the biologically possible range. Big 
Data research often involves combining a number of datasets, which presents challenges. 
Many conditions or clinical episodes will be described by a particular minimum data set; 
however, there may be semantic differences in exactly what is recorded in different 
categories. The definitions of particular episodes or the way in which a given parameter was 
measured may differ between databases.  Specific diseases and conditions may be 
combined or segregated depending on the needs of the data curator; for example, one 
dataset might combine all cardiovascular conditions together, whilst others will list them 
separately. Differences in units for laboratory tests or other measurements are relatively 
easy to overcome by a simple piece of code. This means that difficult decisions may be 
required; converting all the data to the least granular form will mean losing valuable detail, 
but enables the creation of larger datasets. 
Data linkage studies that combine information from different datasets for particular 
individuals require that the data be identifiable. Databases that contain information about 
environment, physical activity, and dietary habits may be of particular relevance in diabetes 
and could provide valuable insights. 
Technologies related to data integration are another important factor that needs 
consideration in Big Data analytics platform.  Data are generated by different sources and 
come in a variety of formats, including unstructured data e.g. with no pre-defined data 
model, such as text and multimedia content. All of these data need to be integrated or 
ingested into Big Data Repositories or Data Warehouses. This involves at least three steps, 
namely, Extract, Transform and Load (ETL). ETL processes have to be tailored for medical 
data to overcome structural, syntactic, and semantic heterogeneity across the different data 
sources.  
Cloud computing models represented by Platform as a Service (PaaS), Software as a Service 
(SaaS) and Infrastructure as a Service (IaaS), ensure quality of service represented by 
dynamic scalability (easily expanded in response to increased demands for network, 
processing, database access or file system resources), low latency (so the application hosted 
on cloud computing will act just like desktop applications), interoperability, and 
performance is a requirement in Big Data analytic cases of clinical and genomic data to 
develop predictive treatment and precision medicine.   
The method of analysis may be pre-determined by the research question. In some 
situations, analysis may be undertaken by machine learning i.e. high-performance 
computing methodologies where the computer finds the way to solve the particular 
problem.  Machine learning can be classified into supervised and unsupervised learning 
methods, that can solve regression, classifications and clustering problems.  There are a 
variety of such techniques including Random Forests, neural networks, and support vector 
  
machines. These advanced analytics can spot patterns that would be difficult (if not 
impossible) for human beings to detect.  
Big Data analytics enable the exploration of data sets to generate hypotheses. The entire 
data set can be analysed to look for unsuspected associations. Many of these may be 
explained by known confounding factors, some will be statistical artefacts (17). Others will 
enable new insights into the condition being studied. For example, the existence of 
differential responses to drugs may be used as a drug discovery tool (26). 
Machine learning techniques may be required for analysis of raw data e.g. in ‘omics’. The 
relationship between particular ‘omics’ is complex, and a neural network may be needed to 
interpret the results. Machine learning can be used to develop systems for automated 
analysis of images. However, the systems being developed are a long way from routine 
clinical use in the developed world (27).  
Big Data and issues specific to healthcare 
There are many claims made for Big Data in healthcare, and some are quite unrealistic (20). 
For example, McKinsey estimates that Big Data could save $200 billion per year in US 
healthcare alone (around 8% of current expenditure). There are some issues specific to 
healthcare that make the use of Big Data more difficult (28). Healthcare data are sensitive in 
nature, and this is reflected in the legal protections. Much Big Data research is performed 
on data collected for another purpose (secondary use). The large number of data subjects 
may make obtaining informed consent impracticable and the demands of the research may 
make anonymisation undesirable e.g. where data linkage is required. This means that the 
research will require authorisation; permission may be required from data access 
committees as well as research ethics committees (for example, the Confidentiality Advisory 
Group in England which advises on access to NHS data).  
The EU General Data Protection Regulation (GDPR) came into force in 2018. The effects on 
data science are relatively minor; blanket consent is not allowed, but broad consent to a 
particular area of research is. Research on sensitive data (which is the category for health-
related data) conducted under the GDPR derogations must be in the public interest. It has 
been clarified that data that has a unique identifier, even when other identifiers have been 
removed (pseudonymised data), must be classified as personal data (29).  
Big Data projects require an appreciation of both the ethico-legal milieu and the socio-
political landscape. Failure to appreciate this led to difficulties with both the UK government 
Care.data project and the Google DeepMind collaboration with the Royal Free Hospital. The 
public is generally supportive of the use of medical data for research, but the researcher 
must not abuse this (30). The requirements of the social licence for research are:  
(i) Reciprocity 
(ii) Non-exploitation 
(iii) Service of the public good (31) 
  
For these criteria to be satisfied, the public need to be included in a dialogue that considers 
their concerns, demonstrates that they will be receiving some value in return for their data, 
and that the wider public good will be served. Research that improves NHS care satisfies the 
requirements of non-exploitation and service of the public good. Data being sold to 
actuaries, without consultation, infringes these requirements (32).  
The issue with the Google DeepMind project was the failure to obtain appropriate 
permission and notify data subjects. It was argued that the data were being used for their 
primary purpose e.g. direct patient care, but the Information Commissioner ruled otherwise 
(33). The data were being used for the development of an algorithm, which would 
eventually benefit patients - but this is not direct patient care and not a purpose that all 
patients presenting to the Royal Free Hospital would have expected that their data would 
be used for (although the subsequent third party audit by Linklaters disagreed with this 
conclusion (34)). 
Big Data and diabetes: current situation 
Current technology and its uses: genomics and precision medicine, image analysis 
There are several sources of data for data research into diabetes as per Table 2 below 
Table 2 Sources of data 
  Electronic health records 
  Smart glucose meters 
  Insulin pumps and automated insulin delivery system 
  Patient-held data e.g. diabetes apps 
  Digital images from retinal screening 
 
Type 2 diabetes is a polygenic disorder, which may be better understood as a group of 
diseases with the common manifestation of hyperglycaemia (35). A number of genes, in 
combination with environmental factors, make a modest contribution to increasing the risk 
of diabetes. More than 120 genetic variants are associated with Type 2 diabetes (36). The 
large number of genes and their moderate effects on risk make genetic screening difficult 
(35). 
This provides great potential for tailoring treatments to the individual patient (whether this 
is called personalised, precision, or stratified medicine) (37). Since different drugs work 
through different mechanisms, some drugs may work better in individuals whose mutations 
affect those specific mechanisms. However, given many patients are affected in several 
different mechanisms, because of the polygenic nature of type 2 diabetes, tailoring a 
specific therapy may be difficult. There are also several other factors to be considered, 
including occupation and general health (38). These would affect the desirability of pursuing 
  
more intensive glycaemic control with the consequently raised risk of hypoglycaemic 
episodes. 
The effect of different treatment regimens is most dramatic in the monogenic forms of 
diabetes, since there is one major mechanism at work. For example, one mutation impairs 
the sensitivity of β-cells to glucose. High-dose sulphonylureas are the specific treatment to 
reverse this (26). A recent study found that the response to sulphonylureas and 
thiazolinediones varied with both BMI and sex (39). The different response to anti-diabetic 
medications may lead to further insights into the pathophysiology of diabetes. 
Pharmacogenetics can therefore be used as a drug discovery tool (26). 
Findings: Scandinavian subgrouping study 
Big Data can produce new nosological insights – for example, a Scandinavian group 
categorized five subgroups of diabetes (40). They looked at one cohort of 8980 patients, 
with replication of the findings in three other cohorts with a total of 5,795 patients. A total 
of 14,775 patients were studied. Six simple variables were analysed at diagnosis: HbA1c, 
BMI, age, HOMA-2B, HOMA2-IR, and GADA status. T1DM and LADA were subsumed under 
severe autoimmune diabetes (SAID). Two new subgroups were further divisions of Type 2 
diabetes – severe insulin-deficient diabetes (SIDD), and severe insulin-resistant diabetes 
(SIRD). They also distinguished mild obesity-related diabetes (MOD) and mild age-related 
diabetes (MARD). However, these subgroups cannot be assumed to represent true 
pathophysiological subgroups. Machine learning is capable of finding patterns in data, but 
the interpretation of these findings may require further hypothesis-driven research. 
Machine learning techniques can also be employed to predict insulin requirements and 
hypoglycaemic episodes (although many patients are very good at this already) (41,42). 
Again, this analysis might lead to subgrouping of people with diabetes in order to improve 
the prediction of glucose levels. It can also be determined which factors are most important 
in the development of particular complications (43). Algorithms can spot trends and provide 
warning of particular events such as hypoglycaemia or worsening organ function (42).  
It can also be used to analyse retinal images; both to act as a substitute for the human eye, 
and to provide insights beyond what the clinician could. Poplin found that computerised 
analysis of retinal images could predict cardiovascular risk using deep learning techniques 
(44). Diabetes can be diagnosed via analysis of the ECG heart rate variability (45).  
Big Data: the future 
As more people with diabetes become connected via the use of apps and automated 
glucose sensors that measure interstitial glucose continuously, the amount of data on 
glycaemic control will expand massively. The clinician will not only be able to assess long-
term control via HbA1c, but also glucose levels minute-to-minute. The data will be available 
easily and in a readily absorbed format. Pills with chips inside will be able to signal when the 
person has taken their medication (46). Improved categorisation of those at risk of Type 2 
diabetes would lead to better and more targeted preventative measures (47).  
  
Artificial intelligence will power apps that provide individualized guidance for people with 
diabetes e.g. adjustments of their treatment regimen and dietary recommendations. 
Monitoring of blood glucose alone does not improve and can have negative effects (24). The 
data gathered from apps will improve the algorithms used for predictions and dose 
calculations. Bluetooth-enabled injection devices could automatically dispense the correct 
amount of insulin. Insulin pumps and automated insulin delivery systems can be controlled 
by software with or without the intervention of healthcare professionals. Connected glucose 
monitors could alert healthcare professionals if the person becomes hypoglycaemic. 
Artificial intelligence could identify what the cause of poor glycaemic control is for 
individuals. Wearable devices that monitor food consumption e.g. by serial photographs of 
food will be able to advise the person on what adjustments to make to their medications, 
and what effect that item is likely to have on their metabolic profile (48). Systems for the 
automated analysis of retinal images will take over the routine task of monitoring 
retinopathy.  
The increasing use of real world data will ensure that the evidence applies to the patient 
group in question. Factors peculiar to a particular ethnic group, locality or institution will be 
rapidly detected. This will enable the benefits of research to apply to the entire patient 
population and will particularly benefit ethnic minorities whose relevant genetic 
characteristics or other factors may differ from the general population. 
Conclusions 
Diabetes is an appealing target for Big Data research for a number of reasons, not least 
because it has a substantial impact on population health that is likely to increase 
significantly over the next few decades. It is a complex, polygenic disorder that is comprised 
of a number of different subtypes. A number of serious complications can occur, and these 
can all be ameliorated by intensive management of blood glucose and other risk factors.  
The overall economic impact of T2DM is huge, once costs of diabetes management, 
treatment of complications, and indirect economic costs, such as lost productivity, are 
included. This means that there is great potential for both new drug discoveries and large 
cost savings. The study of prediabetes holds the promise of reducing the incidence of 
diabetes, either through public health measures or more targeted intervention measures. 
A large amount of healthcare data can be (and ought to be) generated by people with 
diabetes. This ought to be exploited to the maximum extent to develop new insights. It is 
the responsibility of the research community to maximise the benefits. This will require the 
correct approach to data stewardship to ensure ongoing trust. Transparency is key to 
maintaining the social licence. 
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